跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ARV-771
首页
药物
ARV-771
ARV-771
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS
US 2023364243 A1
申请人: BETH ISRAEL DEACONESS MEDICAL CT INC
优先权: 2021
US
WO
2 件公开
Application of pharmaceutical composition in preparation of composition for inhibiting activity of human non-small cell lung cancer cells
CN 116270683 A
申请人: UNIV XIAMEN
优先权: 2022
CN
Degradation agent composition and application thereof
CN 116440139 A
申请人: ZHEJIANG UNIV HANGZHOU INTERNATIONAL SCIENCE AND TECHNOLOGY INNOVATION CENTER
优先权: 2023
CN
Preparation method and application of FD/USCZA nanoparticles with double-sided structure
CN 119258238 A
申请人: UNIV GUANGXI NORMAL
优先权: 2024
CN
BRD4 and p300/CBP double-target degradation agent as well as preparation method and application thereof
CN 120737072 A
申请人: UNIV XINXIANG MEDICAL
优先权: 2025
CN
BRD4 and p300/CBP double-target PROTAC molecule as well as preparation method and application thereof
CN 120682195 A
申请人: UNIV XINXIANG MEDICAL
优先权: 2025
CN
药物
反馈